Highest-materiality recent filing
Corvex Q2 revenue $3.8M, net loss $12.8M; contracted ARR ~$22M
Q2 revenue $3.8M vs $103K prior year; net loss $12.8M ($5.12/share) vs $3.2M loss.
Corvex appoints Seth Demsey co-CEO; preferred shares convert, common outstanding rises to 27.6M
Seth Demsey appointed co-CEO alongside Jay Crystal effective July 1, 2026, following stockholder approval.
Corvex appoints Chance Moreland as CFO effective June 29, 2026
Moreland joins from Morgan Stanley where he was Managing Director in Leveraged & Acquisition Finance.
Corvex Q1 revenue $510k, net loss $(5.1M) after OpCo acquisition; pro forma revenue $3.7M
Completed acquisition of Corvex OpCo on March 19, 2026; renamed from Movano to Corvex.
Corvex (fka Movano) reports pro forma combined Q1 2026 net loss $15.9M post-merger
Pro forma combined Q1 2026 revenue $3.65M, net loss $15.93M ($7.81 diluted EPS).
Corvex Legacy Holdings audited 2025 revenue $7.1M, net loss $9.5M
Audited 2025 revenue of $7.1M; net loss $9.5M driven by $7.1M G&A and $9.6M warrant expense.
Corvex regains Nasdaq minimum equity compliance; subject to one-year monitor
Nasdaq Panel found Corvex compliant with minimum stockholders' equity as of April 7, 2026.
Movano completes reverse merger with Corvex, resolves Nasdaq deficiency, appoints new CEO
Closed merger with Corvex on March 19, 2026; issued convertible preferred shares to Corvex securityholders representing up to 19.9% voting power on as-converted basis.
Movano republishes FY2024 financials after reverse split; revenue $1.0M, going concern noted
Revenue of $1.0M in 2024 (first revenue) vs $0 in 2023; net loss $23.7M vs $29.3M.
Movano stockholders approve 5x share authorization increase and equity line with Chardan
Authorized shares increased from 500M to 2.5B; issuance of >20% of outstanding shares under ChEF Purchase Agreement approved.
Movano to acquire Corvex in reverse merger; Corvex stockholders to own ~96% of combined company
Corvex valued at $250M, Movano at $10M; pre-Merger Corvex holders to own ~96.2% of combined entity.
Movano extends loan maturity to Nov 5, 2025 via amendment with Evie Holdings
Amendment to Loan Agreement with Evie Holdings LLC dated Nov 3, 2025.
Reverse split ratio 1-for-10, effective 12:01 a.m. ET on Oct 10, 2025.
Movano receives Nasdaq delisting notice for equity deficiency
Reported stockholders' equity of $1.637M as of June 30, 2025, below $2.5M minimum.
Movano stockholders approve reverse split and authorized share increase to 2B
Elected Emily Wang Fairbairn (750,312 for) and Michael Leabman (1,030,839 for) as Class I directors.
Nasdaq panel grants Movano Health listing extension through Oct 30, 2025
Deadline to file delinquent Q1 and Q2 2025 10-Qs is Sept 30, 2025; bid price compliance by Oct 30, 2025.
Movano Health receives Nasdaq deficiency notice for late Q2 10-Q; awaits Panel decision on stay
Nasdaq notice received Aug 21, 2025 for failure to file Form 10-Q due Aug 14, 2025.
Movano receives Nasdaq delisting notice; plans to appeal by July 14, 2025
Nasdaq notified Movano on July 7, 2025, that its common stock fails the $1.00 minimum bid price and late filing requirements.
Movano's auditor Moss Adams resigns; prior reports had going concern uncertainty
Auditor Moss Adams LLP resigned effective June 24, 2025, following Movano's exploration of strategic alternatives.
Movano receives Nasdaq deficiency notice for late Q1 10-Q; 60 days to submit plan
Received Nasdaq notice on May 20, 2025 for missing May 15 deadline to file Q1 2025 Form 10-Q.
Movano explores strategic alternatives, delays Q1 10-Q filing due to cash constraints
Board initiated process to explore strategic alternatives including sale or merger; engaged Aquilo Partners and K&L Gates.
Movano Health reports Q3 operating loss $7.4M, ships 339 Evie Rings, reverse split completed
Operating loss of $7.4M in Q3 2024, improved from $9.1M loss in Q3 2023.
Movano Health Q2 2024 operating loss narrows to $6.4M; Evie Ring back in stock Sept 17
Operating loss of $6.4M improved from $7.4M in Q2 2023; no revenue reported as refunds offset deferred revenue.
Movano shareholders approve increase in authorized shares from 150M to 500M and reverse stock split
Stockholders approved certificate amendment increasing authorized common shares from 150,000,000 to 500,000,000.
Movano Health reports Q1 revenue $852k, operating loss $5.8M; closes $24M private placement
Q1 2024 revenue $852,000 from 5,305 Evie Rings shipped; operating loss $5.8M vs $7.2M a year ago.
Movano Health raises $24M, reports Q4 operating loss of $6.0M, achieves FDA accuracy milestone
Executed $24M private placement including $3.0M from a tier-1 medical device company and $3.6M from insiders.
Movano raises ~$24.2M in private placement of units with warrants
Raised ~$24.2M gross via 45.3M units at $0.533/unit (directors/officers at $0.565/unit).
Movano Health reports over $1M in Evie Ring orders; cuffless BP tech passes FDA accuracy standard
Over $1M in orders during Black Friday holiday launch of Evie Ring smart ring for women.
Movano receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notice dated Nov 14, 2023: common stock bid price below $1.00 for 30 consecutive days.
Movano Health to launch Evie Ring Nov 20; reports Q3 net loss $9.0M
Evie Ring launches Nov 20 at $269 with no subscription; shipping expected by year-end.
Movano Health prices $3.6M public offering of 4.2M shares at $0.85/share
Offering of 4,235,304 shares of common stock at $0.85 per share, gross proceeds of $3.6M.
Movano Health reports Q2 net loss $7.3M; Evie Ring launch planned before Black Friday 2023
Net loss $7.3M ($0.17 per share) vs $6.9M loss ($0.21 per share) in Q2 2022; no revenue.
Movano Health prices $8.0M public offering of 8M shares at $1.00 per share
Gross proceeds of $8.0M from offering of 8,000,000 shares at $1.00/share.
Movano Health Q1 2023 net loss $7.1M; Evie Ring launch planned September at $269
Net loss of $7.1M ($0.19 per share) in Q1 2023 vs $6.9M loss in Q1 2022; no revenue generated.
Movano raises $5.8M in underwritten public offering of common stock and warrants
Offered 4,644,000 shares at $1.40 each plus one warrant per two shares.
Movano Health reports Q3 net loss of $8.6M; progress on FDA submission and beta programs
Net loss of $8.6M ($0.26 diluted EPS) vs $5.2M ($0.16) in Q3 2021; no revenue.
Movano Q2 net loss $6.9M; advances Ring beta tests, hypoxia study meets FDA SpO2 accuracy
Net loss $6.9M ($0.21/sh) vs $4.7M ($0.15/sh) in Q2 2021; no revenue as development-stage company.
Movano appoints Nan Kirsten Forte to board, expands board to six
Board expanded from five to six; Forte appointed as Class III director until 2024 annual meeting.
On January 2, 2025, the Board of Directors (the “Board”) of Movano Inc. (the “Company”) appointed Shaheen Wirk as a Class III director.
approved an increase in the size of the Board from five to six directors and appointed Nan Kirsten Forte as a Class III director
Max materiality 0.90 · Median 0.65 · Most common event other_material